Gilead Sciences Inc

GILD: XNAS (USA)
View Stock Summary
Morningstar Rating for StocksFair ValueEconomic MoatCapital Allocation
LOCK|gTLOCK|S#JLOCK|>@sBy>

Gilead: Arcellx Acquisition Shows Conviction in Anito-Cel's Potential Versus J&J's Carvykti

Gilead is acquiring partner Arcellx for $7.8 billion upfront, giving it full rights to multiple myeloma cell therapy anito-cel. The acquisition is expected to close in the second quarter.

Sponsor Center